These are amazing times … a gene therapy can restore sight.
And now you can help to restore sight for someone going blind. Here is how…
42 Canadians are counting on you. Their blindness is caused because their RPE65 gene is not functioning, and they are losing approximately 10,000 precious light sensing eye cells a day.
And time is growing short for these Canadians. It is taking 18 to 24 months for the drug approval process to slowly figure out if they will public fund Luxturna in your province. Some of these Canadians may not have enough light sensing eye cells left by the time a decision is made.
Please add your voice by sending an email to your Premier. We must accelerate the negotiations for public health care to fund Luxturna. We must set the precedent for future vision treatments that they will be funded too.
Health Canada approved Luxturna as a treatment in Canada in October 2020. A few weeks later, the Canadian Agency for Drugs and Technologies in Health (CADTH) and in Quebec, l’Institut national d’excellence en santé et en services sociaux (INESSS) recommended Luxturna for public health care funding.
The next step is the pan-Canadian Pharmaceutical Alliance (pCPA) to negotiate a deal on Luxturna. pCPA is an alliance of the provincial, territorial and federal governments that negotiates these deals that lead the way to public health care funding of a treatment.
BUT pCPA has not started the Luxturna negotiations for over 5 months.
Time = Sight!
We just can’t let a bureaucratic process mean someone goes blind when a treatment is available. We’ve waited too long for this first treatment. We need to encourage more treatments to reach Canadians by setting the precedent with Luxturna that all treatments can be funded by public health care.
That’s why we launched our latest “Approve Luxturna” Advocacy Campaign.
We are asking all of our supporters to send an email to the Premier, local representatives and the pCPA and demand action now.
Please take one minute and add your name here: